Sonstige Psychopharmaka

  • M. Hollweg
  • R. Grohmann
  • E. Rüther


  • Mit Chloralhydrat behandelte Patienten insgesamt: 5755

  • In Überwachung durch Intensiverfassung: 454

  • In Überwachung durch Absetz-UAW-Erfassung: 5301


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Brown AM, Cade JF (1980) Cardiac arrhytmias after chloral hydrate overdose. Med J Aust 1: 28PubMedGoogle Scholar
  2. Jerram T (1984) Hypnotics and sedatives. In: Dukes MNG (ed) Side effects of drugs. Elsevier Science Publishers, New York, pp 81–94Google Scholar
  3. Miller RR, Greenblatt DJ (1979) Clinical effects of chloral hydrate in hospitalized medical patients. J Clin Pharmacol 19: 669PubMedGoogle Scholar
  4. Reynolds JEF (ed) (1989) Martindale - the extra pharmacopoeia. The Pharmaceutical Press, London, p 717Google Scholar
  5. Shapiro S, Sione D, Lewis GP, Jick H (1969) Clinical effects of hypnotics. JAMA 209: 2016–2020PubMedCrossRefGoogle Scholar
  6. Beckmann H, Moises HW (1982) The cholinolytic biperiden in depression. Arch Psychiat. Nervenkr 231: 213–220Google Scholar
  7. DiMascio A, Demirgian A (1970) Antiparkinsonian drug overuse. Psychosomatics 11: 506–601Google Scholar
  8. Hall RCW, Feinsilver DL, Holt RE (1981) Anticholinergic psychosis: Differential diagnosis and management. Psychosomatics 22: 581–587PubMedGoogle Scholar
  9. Jellinek T (1977) Mood elevating effect of Trihexypenidyl and Biperiden in individuals taking antipsychotic medication. Dis Nerv Syst 38:353–355PubMedGoogle Scholar
  10. Reynolds JEF (ed) (1989) Martindale - the extra pharmacopoeia. The Pharmaceutical Press, London, p 529Google Scholar
  11. Tornatore FL, Sramek JJ, Okya BL, Pi EH (1991) Unerwünschte Wirkungen von Psychopharmaka. Thieme, Stuttgart New York, S 165Google Scholar
  12. Hession MA, Verma S, Mohan Bakta KG (1979) Dependence on clormethiazole and effects of its withdrawal. Lancet 1: 953PubMedCrossRefGoogle Scholar
  13. Illingworth RN, Stewart MG, Jarvie DR (1979) Severe poisoning with clormethiazole. Br Med J [Clin Res] 284: 705Google Scholar
  14. Reynolds JEF (ed) (1989) Martindale - the extra pharmacopoeia. The Pharmaceutical Press, London, p 720Google Scholar
  15. Askmark H, Wilholm BE (1990) Epidemiology of adverse reactions to carbamazepine as seen in a spontaneous reporting system. Acta Neurol Scand 81: 131PubMedCrossRefGoogle Scholar
  16. Ballenger JC, Post RM (1980) Carbamazepine in manic-depressive illness: a new treatment. Am J Psychiatry 137: 782–790PubMedGoogle Scholar
  17. Boese F, Andersen EB, Jensen EK, Ladefoded SD (1983) Cardiac conduction disturbances during carbamazepine therapy. Acta Neurol Scand 68: 49–52Google Scholar
  18. Booker HE (1975) Idiosyncratic reactions to antiepileptic drugs. Epilepsia 16: 171–181PubMedCrossRefGoogle Scholar
  19. Elphik M (1987) Effect of carbamazepine on some behavioral models of monoamine function. Br J Pharmacol 92: 665Google Scholar
  20. Greil W, Schmidt S (1989) Notwendigkeit von Alternativen zur Lithiumprophylaxe aus klinischer Sicht. In: Müller-Oerlinghausen B et al. (Hrsg) Carbamazepin in der Psychiatrie. Thieme, Stuttgart New York, S 112Google Scholar
  21. Höpen G, Nesthus I, Laerum O (1981) Fatal CBZ-associated hepatitis. Acta Med Scand 210: 233–235Google Scholar
  22. Horowitz S, Parwardhan R, Marcus E (1988) Hepatotoxic recations associated with carbamazepine therapy. Epilepsia 29: 149–154PubMedCrossRefGoogle Scholar
  23. Mitchell MC, Boitnott JK, Arregui A et al. (1981) Granulomatous hepatitis associated with carbamazepine. Am J Med 71: 733PubMedCrossRefGoogle Scholar
  24. Okuma T, Inanaga K, Otsuki S et al. (1979) Comparison of the anti-manic efficacy of carbamazepine and chlorpromazine: A double-blind controlled study. Psychopharmacology (Berlin) 55: 211–217CrossRefGoogle Scholar
  25. Pakesch E (1963) Untersuchungen über ein neuartiges Antiepilepticum. Wien Med Wochenschr 113: 329–343Google Scholar
  26. Parkes JD (1982) Adverse effects of anti-parkinsonian drugs. Curr Ther 4: 61–69Google Scholar
  27. Pisciotta AV (1982) Carbamazepine. Hematological toxicity. In: Woodbury DM, Penry JK, Pippenger CE (eds) Antiepileptic drugs. Raven, New York, pp 53–541Google Scholar
  28. Schmutz M, Klebs K, Mondadori C, Olpe HR (1987) Das pharmakologische Profil des Carbamazepin. In: Krämer G, Hopf HC (Hrsg) Carbamazepin in der Neurologie. Thieme, Stuttgart New York, S 2Google Scholar
  29. Sillanpää M (1987) Das klinische Profil von Carbamazepin. Nutzen, Risiko und Optimierung der Therapie. In: Krämer G, Hopf HC (Hrsg) Carbamazepin in der Neurologie. Thieme, Stuttgart New York, S 102Google Scholar
  30. Steiner C, Wit AL, Weiss MB, Damato AN (1970) The antiarrhythmic actions of carbamazepine (Tegretol). J Pharmacol Exp Ther 173: 323–335PubMedGoogle Scholar
  31. Takezaki H, Hanaoka M (1971) The use of carbamazepine (Tegretol) in the control of manic-depressive psychosis and other manic depressive status. J Clin Psychiatry 13:173–183Google Scholar
  32. Woodbury DM, Penry JK, Pippenger CE (eds) (1982) Antiepileptic drugs. Raven Press, New York, pp 52–141Google Scholar
  33. Zucker P, Damm F, Cohen M (1977) Fatal carbamazepine hepatitis. Pediatrics 91:667–668CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • M. Hollweg
  • R. Grohmann
  • E. Rüther

There are no affiliations available

Personalised recommendations